ClinicalTrials.Veeva

Menu

The Effect Of Glycemic Control On Malondialdehyde, Glutathione Peroxidase, Glutathione And Paraoxonase

S

Suleyman Demirel University

Status

Completed

Conditions

Type 2 Diabetes Mellitus
Chronic Periodontitis

Study type

Observational

Funder types

Other

Identifiers

NCT01467674
1721-D-08

Details and patient eligibility

About

The aim of this study was to investigate the impact of glycemic control on clinical periodontal status, levels of malondialdehyde (MDA), glutathione peroxidase (GSH-Px), reduced glutathione (GSH) and paraoxonase (PON) activity in gingival crevicular fluid (GCF) and blood samples of type 2 diabetes mellitus (T2DM) patients with chronic periodontitis (CP).

Full description

Reactive oxygen species (ROS) are products of normal cellular metabolism and play beneficial role in physiological functions. Overproduction of ROS and/or deficiency of enzymatic or non-enzymatic antioxidants, termed as oxidative stress, is involved in many pathological conditions such as Diabetes mellitus (DM) and chronic periodontitis (CP).

Several researches revealed that DM, with many determinants such as level of glycemic control, stands as a strong risk factor for periodontal diseases. On the other side, periodontal diseases induce an elevated chronic inflammatory state and exacerbated insulin resistance.

In the present study, the investigators examined the effect of glycemic control level on clinical periodontal status, levels of MDA, GSH-Px, GSH and PON activity in gingival crevicular fluid and blood samples of CP patients with T2DM.

Enrollment

84 patients

Sex

All

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • to present T2DM diagnosis by an endocrinologist for at least the past 5 years
  • diagnosis of CP was based on the clinical and radiographic criteria proposed by the 1999 World Workshop for Classification of Periodontal Diseases and Conditions

Exclusion criteria

  • pregnancy
  • lactation
  • current smoking or smoking within the past 2 years, periodontal therapy in the previous 6 months
  • antibiotic and/or antimicrobial therapies in the previous 3 months
  • existence of serious diabetic complications or any pathology such as haemoglobinopathy which would affect haemoglobin profile
  • diagnosis of another major medical pathology, middle or upper-level obesity according to WHO classification
  • current anti-hyperlipidemic therapy
  • non-T2DM patients with abnormal values of glucose and lipid metabolism parameters, major medical pathology and family history of DM

Trial design

84 participants in 4 patient groups

Healthy
Chronic Periodontitis
Better Controlled T2DM
Poor Controlled T2DM

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems